| Andover Podiatry Pc | |
|
107 Main St, Andover, MA 01810-3803 | |
| (978) 475-1313 | |
| (978) 475-1166 |
| Full Name | Andover Podiatry Pc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist |
| Location | 107 Main St, Andover, Massachusetts |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1902015142 | NPI | - | NPPES |
| 9738584 | Medicaid | MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 1991 (Massachusetts) | Primary |
| Provider Name | Adam M Lang |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1518257468 PECOS PAC ID: 5698994291 Enrollment ID: I20150903001156 |
News Archive
Gilead Sciences, Inc. today announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy. This decision follows an interim analysis of unblinded efficacy and safety data by the study's Data Monitoring Committee (DMC) and review of those data by Gilead, which did not show evidence of a treatment benefit in the group of patients randomized to receive ambrisentan.
Resolvin E1, a molecule produced naturally in the body from an omega -3 fish oil, topically applied on gum tissues not only prevents and treats gum disease as previously shown (Hasturk et al 2006 and 2007), but also decreases the likelihood for advanced arterial atherosclerotic plaques to rupture and form a dangerous thrombus or blood clot.
Epilepsy is one of the most common neurological conditions, affecting more than 65 million worldwide. For those dealing with epilepsy, the advent of a seizure can feel like a ticking time bomb.
Growing up in a well-off home can benefit a child's physical health even decades later — but a lack of parent-child warmth, or the presence of abuse, may eliminate the health advantage of a privileged background, according to a Baylor University study.
› Verified 3 days ago
| Provider Name | Sarah M Montgomery |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1376053694 PECOS PAC ID: 8325302078 Enrollment ID: I20180503001699 |
News Archive
Gilead Sciences, Inc. today announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy. This decision follows an interim analysis of unblinded efficacy and safety data by the study's Data Monitoring Committee (DMC) and review of those data by Gilead, which did not show evidence of a treatment benefit in the group of patients randomized to receive ambrisentan.
Resolvin E1, a molecule produced naturally in the body from an omega -3 fish oil, topically applied on gum tissues not only prevents and treats gum disease as previously shown (Hasturk et al 2006 and 2007), but also decreases the likelihood for advanced arterial atherosclerotic plaques to rupture and form a dangerous thrombus or blood clot.
Epilepsy is one of the most common neurological conditions, affecting more than 65 million worldwide. For those dealing with epilepsy, the advent of a seizure can feel like a ticking time bomb.
Growing up in a well-off home can benefit a child's physical health even decades later — but a lack of parent-child warmth, or the presence of abuse, may eliminate the health advantage of a privileged background, according to a Baylor University study.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andover Podiatry Pc 107 Main St, Andover, MA 01810-3803 Ph: (978) 475-1313 | Andover Podiatry Pc 107 Main St, Andover, MA 01810-3803 Ph: (978) 475-1313 |
News Archive
Gilead Sciences, Inc. today announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy. This decision follows an interim analysis of unblinded efficacy and safety data by the study's Data Monitoring Committee (DMC) and review of those data by Gilead, which did not show evidence of a treatment benefit in the group of patients randomized to receive ambrisentan.
Resolvin E1, a molecule produced naturally in the body from an omega -3 fish oil, topically applied on gum tissues not only prevents and treats gum disease as previously shown (Hasturk et al 2006 and 2007), but also decreases the likelihood for advanced arterial atherosclerotic plaques to rupture and form a dangerous thrombus or blood clot.
Epilepsy is one of the most common neurological conditions, affecting more than 65 million worldwide. For those dealing with epilepsy, the advent of a seizure can feel like a ticking time bomb.
Growing up in a well-off home can benefit a child's physical health even decades later — but a lack of parent-child warmth, or the presence of abuse, may eliminate the health advantage of a privileged background, according to a Baylor University study.
› Verified 3 days ago
Dr. Adam M Lang, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 107 Main St, Andover, MA 01810 Phone: 978-475-1313 Fax: 978-475-1166 |